Denali Therapeutics Inc’s recently made public that its Director Krognes Steve E. unloaded Company’s shares for reported $0.87 million on Sep 30 ’24. In the deal valued at $29.03 per share,30,000 shares were sold. As a result of this transaction, Krognes Steve E. now holds 29,096 shares worth roughly $0.77 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, STEVE KROGNES bought 30,000 shares, generating $882,900 in total proceeds.
Before that, SATO VICKI L sold 1,020 shares. Denali Therapeutics Inc shares valued at $30,600 were divested by the Director at a price of $30.00 per share. As a result of the transaction, SATO VICKI L now holds 115,156 shares, worth roughly $3.06 million.
Cantor Fitzgerald downgraded its Denali Therapeutics Inc [DNLI] rating to a Neutral from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating.
Price Performance Review of DNLI
On Monday, Denali Therapeutics Inc [NASDAQ:DNLI] saw its stock fall -7.09% to $26.60. Over the last five days, the stock has lost -8.69%. Denali Therapeutics Inc shares have risen nearly 23.95% since the year began. Nevertheless, the stocks have risen 25.83% over the past one year. While a 52-week high of $32.13 was reached on 09/18/24, a 52-week low of $14.56 was recorded on 04/25/24. SMA at 50 days reached $25.98, while 200 days put it at $21.18.
Levels Of Support And Resistance For DNLI Stock
The 24-hour chart illustrates a support level at 25.92, which if violated will result in even more drops to 25.23. On the upside, there is a resistance level at 27.59. A further resistance level may holdings at 28.57. The Relative Strength Index (RSI) on the 14-day chart is 41.72, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.56, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 93.57%. Stochastics %K at 8.71% indicates the stock is a buying.
How much short interest is there in Denali Therapeutics Inc?
A steep rise in short interest was recorded in Denali Therapeutics Inc stocks on 2024-09-13, growing by 1.03 million shares to a total of 9.4 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 8.36 million shares. There was a rise of 11.0%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 06, 2023 when B. Riley Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $38 price target.
